OPKO Health (OPK)
Runs BioReference diagnostics alongside Rayaldee and NGENLA economics.
Something off on this page? Send us feedback.
Operates a healthcare portfolio split between BioReference diagnostics and pharmaceuticals, including international drug operations, Rayaldee, NGENLA economics through Pfizer, and ModeX collaborations. Diagnostics is now concentrated in core New York and New Jersey testing plus 4Kscore, while pharmaceuticals depend on product sales, royalties, contract revenue, and partner-led R&D.
Runs two reportable segments: Pharmaceuticals and Diagnostics. Pharmaceuticals includes drug operations spanning Latin America, Europe, and Israel, Rayaldee sales, NGENLA royalty and profit-sharing economics with Pfizer, and pharmaceutical R&D. Diagnostics centers on BioReference clinical laboratory operations and point-of-care operations.
BioReference is narrower after the sale of selected oncology-related testing assets to Labcorp. Continuing diagnostics focus on core clinical testing in the New York and New Jersey region and the 4Kscore Test franchise, a prostate cancer biopsy decision tool built around blood markers and an algorithm.
Execution depends on reimbursement, test volume, Rayaldee demand, Pfizer-driven NGENLA economics, BARDA and other contract revenue, and ModeX collaboration progress. BioReference also operates under a Corporate Integrity Agreement tied to compliance governance and reporting.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Apr 29, 2026 | Barrington Research | Downgrade | ||
| Oct 31, 2025 | Jefferies | Downgrade | ||
| Oct 30, 2025 | Jefferies | Target | Target: — | Target: $1.60 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $300.8M · Total debt $392.3M · Total assets $1.83B · Shareholders' equity $1.18B
- Revenue
- $163.6M
- Operating income
- −$7.0M
- Net income
- −$8.4M
No dividends on record.
| Institutions | 27.60% | 206.02M shares | |
|---|---|---|---|
| 229 holders · as of Jun 30, 2026 | |||
| Insiders | 45.97% | 343.08M shares | |
| 7 holders · as of Jul 28, 2026 | |||
| Other | 26.43% | 197.23M shares | |
| remainder | |||
746.33M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Phillip Md Et Al FrostInsiderdirector, 10 percent owner, officer: CEO & Chairman | 34.22% | 255.43M | filed Jul 1, 2026 |
Rubric Capital Management LPInstitution | 6.40% | 47.79M | as of Jun 30, 2026 |
Bruce C. HolbrookInsider | 5.33% | 39.78M | filed Jun 29, 2022 |
Coe M. MagruderInsider | 5.32% | 39.72M | filed Jun 29, 2022 |
BlackRock, Inc.Institution | 4.95% | 36.98M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Mar 20, 2026 | John A. Paganelli | director | +10,000 | $1.14 |
| Nov 21, 2025 | Phillip Md Et Al Frost | director, 10 percent owner, officer: CEO & Chairman | +580,000 | $1.33 |
| Nov 20, 2025 | Phillip Md Et Al Frost | director, 10 percent owner, officer: CEO & Chairman | +580,000 | $1.33 |
| Nov 19, 2025 | Phillip Md Et Al Frost | director, 10 percent owner, officer: CEO & Chairman | +580,000 | $1.31 |
| Nov 18, 2025 | Phillip Md Et Al Frost | director, 10 percent owner, officer: CEO & Chairman | +533,300 | $1.27 |
- Quest Diagnostics
Core lab scale rival in NY/NJ clinical testing
- Labcorp
Large lab rival with direct BioReference asset overlap
- MDxHealth
Urology diagnostics peer around prostate-risk tests
- Novo Nordisk (ADR)
Weekly growth-hormone rival through Sogroya
- Ascendis Pharma (ADR)
Weekly growth-hormone rival through Skytrofa
- Teva (ADR)
Broad generic-pharma peer for international product operations
- Amgen
Renal SHPT therapy peer through calcimimetic products
- Xencor
Engineered-antibody platform peer in multispecific R&D
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| OPKO Health | $1.72 | −0.87% | $1.29B | — | — | 2.2 | +4.3% |
| Quest Diagnostics | $233.59 | −0.50% | $25.92B | 24.9 | 20.4 | 2.2 | +10.2% |
| Labcorp | $304.65 | −2.21% | $25.55B | 25.8 | 16.1 | 1.8 | +5.8% |
| MDxHealth | $0.6066 | +1.12% | $30.8M | — | — | 0.4 | −0.8% |
| Novo Nordisk (ADR) | $38.31 | −2.77% | $174.96B | 9.9 | 15.8 | 3.5 | +1.3% |
| Ascendis Pharma (ADR) | $224.44 | −5.53% | $14.76B | 18.2 | 31.7 | 12.3 | +108.2% |
| Teva (ADR) | $39.19 | −0.84% | $46.03B | 65.9 | 14.0 | 2.7 | −0.8% |
| Amgen | $405.69 | −1.11% | $221.41B | 25.5 | 17.3 | 5.8 | +9.7% |
| Xencor | $24.51 | −2.59% | $1.87B | — | — | 17.8 | +17.5% |
| Median | 25.2 | 16.7 | 3.1 | +7.7% |